ULTRAGENYX PHARMACEUTICAL INC. Contractual Obligation, to be Paid, Year One
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Contractual Obligation, to be Paid, Year One of $30.41 million as of 2020-12-31, per its 10-K filed 2021-02-12.
Discontinued › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity
us-gaap:ContractualObligationDueInNextTwelveMonths · last filed 2021-02-12
- 2020-12-31: Contractual Obligation, to be Paid, Year One $30.41M.
- 2019-12-31: Contractual Obligation, to be Paid, Year One $7.85M.
- 2018-12-31: Contractual Obligation, to be Paid, Year One $6.79M.
- 2017-12-31: Contractual Obligation, to be Paid, Year One $7.54M.
| Period end | Contractual Obligation, to be Paid, Year One |
|---|---|
| 2020-12-31 | $30.41M 10-K · filed 2021-02-12 |
| 2019-12-31 | $7.85M 10-K · filed 2020-02-14 |
| 2018-12-31 | $6.79M 10-K · filed 2019-02-20 |
| 2017-12-31 | $7.54M 10-K · filed 2018-02-21 |
| 2016-12-31 | $1.96M 10-K · filed 2017-02-17 |
| 2015-12-31 | $2.04M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |